Nolotil and its ethnically targetted side effects

All Hi-Tech Developments for the Military and Civilian Sectors
Post Reply
Micael
Posts: 7353
Joined: Thu Nov 17, 2022 10:50 am

Nolotil and its ethnically targetted side effects

Post by Micael »

This is kind of interesting, I’ve heard something more vague about it in the past but this seems a lot more solid, that Britons and to a degree other northern Europeans are much more likely to suffer a severe side effect from this medication than other populations.

Auto-translated from El Pais:
A study uncovers nine deaths from the use of Nolotil in two years in Alicante, seven of them British patients
The research suggests that UK citizens are up to 120 times more likely than Spaniards to suffer serious reactions to the drug

ORIOL GÜELL
Barcelona - 16 NOV 2026 - 05:30 CET

A presentation given at the recent congress of the Spanish Society of Hospital Pharmacy (SEFH) by officials from the Francesc de Borja Hospital in Gandía reveals previously unknown data from the Spanish Pharmacovigilance System that highlight safety concerns related to metamizole, particularly among citizens of the United Kingdom. This molecule is the active ingredient in Nolotil —Spain's best-selling brand-name medication—indicated for pain and high fever.


The communication, also presented at the last European congress of the specialty, is based on data from an internal report by the Valencian Regional Government prepared in 2019 that has never been published and to which EL PAÍS has now gained access. Its title is " Incidence of metamizole-induced agranulocytosis in the European population residing in the province of Alicante (2016-2017) ," and it analyzes serious adverse reactions during those two years in five health departments : Denia, Villajoyosa, Torrevieja, San Juan, and Orihuela. These areas have the highest concentration of foreign residents and a combined population of 916,000, of whom 62,000 were from the United Kingdom (6.7%) and 28,000 from other northern European countries.



During that two-year period, the study reveals, nine people died from metamizole-induced agranulocytosis, seven of them British and two Spanish. This clinical condition is the most well-known serious adverse effect of the drug , a potentially fatal and drastic decrease in granulocytes—a type of white blood cell. In total, the study identified 41 hospitalized patients with metamizole-induced agranulocytosis, of whom 26 were British, 11 Spanish, one Danish, one Dutch, one Swedish, and one Moroccan.

To conduct the analysis, researchers cross-referenced hospital discharge databases— the Minimum Basic Data Set (MBDS) —with outpatient use of the drug in individuals over 45 years of age during 2016 and 2017, and reviewed each medical record to confirm that the patients had taken metamizole in the month prior to hospitalization. To narrow down the relationship with the medication, patients whose weakened immune system could have other causes—infections, medications, cancer, etc.—were excluded.

A key aspect of the study is the comparison of the relative risk of developing agranulocytosis from Nolotil in British patients compared to Spanish patients, which is carried out in two ways. The first is through the analysis of defined daily doses (DDDs)—the most commonly used indicator for comparing drug consumption—in each group. Among the Spanish patients, there were 0.33 cases per 100,000 DDDs, a rate that skyrocketed to 39.8 cases among people from the United Kingdom (a risk 120.7 times higher).


The second method involves the number of agranulocytosis events per 1,000 patients who had taken metamizole. Among Spanish nationals, the rate is 0.084 cases per 1,000 treated patients (almost one in 12,000), while among British nationals this figure rises to 6.62 (one in 151). This represents a relative risk 78.8 times higher.

The study provides relevant information on a controversy that has been ongoing for decades. Metamizole was first marketed in Germany in 1922 and remains widely used there, as well as in Austria, Italy, Portugal, Russia, and Turkey, among other countries. It is still approved in Belgium and the Netherlands, but its use is highly restricted. In contrast, France, Sweden, Denmark, the United Kingdom, Ireland, the United States, and some thirty other countries have withdrawn it due to its link to agranulocytosis.

The possibility that genetic factors may cause adverse reactions to be more frequent in some populations is the subject of recurring debates, although the truth is that there are practically no solid comparative studies. The Spanish Agency for Medicines and Health Products (AEMPS) maintains that “the available information does not allow us to rule out or confirm a greater risk in populations with specific ethnic or genetic characteristics.” The agency also argues that the balance between the benefits and risks of metamizole remains positive.


In the last decade, however, there have been repeated warnings in Spain about problems with metamizole use in people of Northern European origin. Most of these warnings have come from hospitals in areas with a high foreign population (Costa del Sol, Denia, etc.), whose centers have adopted specific measures to prevent risks. These cases have led to several lawsuits, most of which are still ongoing.

In 2018, the Spanish Agency for Medicines and Health Products (AEMPS) published a statement recommending against using the drug for more than a week and advising against its use among transient populations. “The statement refers to tourists, when [the risk] is really with people from these countries residing here,” criticized José Luis Marco Garbayo, the study's author, at a SEFH event. He declined to be interviewed by this newspaper.

A new chapter unfolded between 2023 and 2024, when the European Medicines Agency (EMA) reassessed the drug's safety after Finland decided to withdraw it. The EMA concluded that the drug's benefits still outweighed the risks, although it did promote changes to the package inserts to facilitate the detection of complications.


Regarding the report from the Valencian Regional Government, the Spanish Agency for Medicines and Health Products (AEMPS) has issued a written statement questioning the validity of its conclusions: “It has significant limitations because it is descriptive, not analytical. It does not allow for the calculation of incidences or relative risks, which is crucial for evaluating the safety profile.” The agency adds that “neither the study design, nor the method used to calculate the frequency measures, nor the estimation of relative risk, nor the lack of control for other biases support the conclusion offered.”

The Spanish Agency for Medicines and Health Products (AEMPS) highlights another study of its own, published in 2024 in the European Journal of Clinical Pharmacology using data from the Database for Pharmaco-epidemiological Research in Primary Care (BIFAP). Its main conclusion is that “agranulocytosis was very rare, but more common with metamizole than with other analgesics (more than four times higher).” However, the study clarifies that the small number of cases analyzed makes it impossible to rule out that the observed differences were due to chance.

The AEMPS's responses, however, leave two key questions unanswered. The first is that its BIFAP study does not separate the studied population by country of birth (the database does not record this data), which prevents the study from shedding light on whether or not there is a greater risk among the British population.


The second issue concerns the underreporting of many drug-related problems, which makes it impossible to have a complete picture of the problem in Spain. The Spanish Agency for Medicines and Health Products (AEMPS) admits that it does not know whether the nine deaths in Alicante were reported to the system: “The inclusion of these cases in the FEDRA database [of adverse effects] depends on whether they have been reported by healthcare professionals or members of the public. Since the information is anonymized, it is not possible to determine this.” The agency has not provided this newspaper with data on cases of agranulocytosis registered in the country.

Vicente Palop, from the working group on medication use of the Spanish Society of Family and Community Medicine (semFYC), is critical of the drug safety management. “There is a serious problem with transparency and reporting. We don't know the real impact of adverse effects. And not only in the population of Northern Europe, but also among Spaniards. While other countries are acting decisively, like Finland, the Spanish Agency for Medicines and Health Products (AEMPS) seems to prefer ignoring or discrediting reports that point to the problem instead of implementing the necessary measures to determine its true extent,” he criticizes.

Oriol Güell
https://elpais.com/salud-y-bienestar/20 ... campaign=x
Post Reply